ClinicalTrials.gg
CompletedNCT00681031Updated Jun 29, 2021Results posted

Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)

A Phase 4 interventional study of ZOSTAVAX® in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
96
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
18th of 29
96 · median 160
Started
2008
the only one that year
Phase 4
8 of 29
none open now
Registered
8th of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 18th largest by enrollment, is the only one that started in 2008, is one of 8 in phase 4, and was the 8th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

Primary objective:

To demonstrate whether or not ZOSTAVAX® at minimum release specification approaching expiry potency elicits an acceptable Varicella-Zoster Virus (VZV) antibody fold rise (measured by glycoprotein Enzyme Linked ImmunoSorbent Assay [gpELISA]) from pre-vaccination to 4 weeks post-vaccination.

Secondary objectives:

To describe the safety profile of ZOSTAVAX® at minimum release specification approaching expiry potency.

03

Conditions studied

  • Herpes Zoster

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant of either gender aged ≥50 years
  • Positive history of varicella or residence for >30 years in a country with endemic VZV infection
  • All females must be or have a negative serum or urine pregnancy test or acceptable method of for three months after vaccination
  • Participant having signed the form prior to any study procedure

Exclusion criteria

Exclusion Criteria:

  • Febrile within 72 hours prior to vaccination
  • Prior history of Herpes Zoster clinically diagnosed by a physician
  • Previously received a varicella or zoster vaccine
  • Exposure to varicella or herpes-zoster within 4 weeks prior to vaccination
  • Received any other within 4 weeks prior to vaccination, or is expected to receive any other live virus vaccine during the study
  • Received any inactivated vaccine within 2 weeks prior to vaccination, or is expected to receive any inactivated vaccine during the study
  • Was treated with immunoglobulins or any blood products, other than autologous blood transfusion, given during the 5 months prior to vaccination or is expected to be treated during the study
  • Taking any non topical antiviral therapy with activity against herpesviruses.
  • On therapy
  • Known or suspected immune dysfunction caused by a medical condition, or any other cause
  • History of reaction or anaphylactoid reaction to any vaccine component, including gelatin or neomycin
  • Known active tuberculosis
  • Significant underlying illness preventing completion of the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    All Enrolled

    Participants received a single dose (0.65 mL) of shingles (herpes zoster) vaccine (live) ZOSTAVAX® by subcutaneous injection at Visit 1 (Day 0)

    Biological: ZOSTAVAX®

Interventions

  • BiologicalZOSTAVAX®

    One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live attenuated) not less than 19400 PFU

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titre (GMT) of Varicella Antibodies

    Blood samples to determine the GMT of varicella antibodies taken pre-vaccination and again 28 to 35 days post vaccination. Titres determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA).

    Time frame: Predose (Day 0) and Day 28-35 Post Dose

07

Results

Posted Sep 26, 2017

Participant flow

Participant flow — Overall Study
MilestoneAll Enrolled
Started96
Completed96
Not completed0

Outcome measures

PrimaryGeometric Mean Titre (GMT) of Varicella Antibodies

Blood samples to determine the GMT of varicella antibodies taken pre-vaccination and again 28 to 35 days post vaccination. Titres determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA).

Time frame:
Predose (Day 0) and Day 28-35 Post Dose
Reported as:
Geometric mean · gpELISA units/mL
Geometric Mean Titre (GMT) of Varicella Antibodies
gpELISA units/mLAll Enrolled
Predose215.8 (178.1 to 261.4)
Postdose674.0 (565.4 to 803.5)
Statistical analysis
  • All Enrolled · Gmfr: 3.1 · 95% CI 2.6 to 3.8GMFR = GMT postdose divided by GMT predose

Adverse events

Collected over Up to 35 days post vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
V211—0/96 (0%)50/96 (52.1%)
Most frequent other events
Most frequent other events
EventV211
Injection site painGeneral disorders39/96
Injection site erythemaGeneral disorders36/96
Injection site swellingGeneral disorders21/96

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Enrolled
Mean62.2 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled
Female50
Male46
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Arnou R, Fiquet A, Thomas S, Sadorge C. Immunogenicity and safety of ZOSTAVAX((R)) approaching expiry potency in individuals aged >/=50 years. Hum Vaccin. 2011 Oct;7(10):1060-5. doi: 10.4161/hv.7.10.16480. Epub 2011 Oct 1. PubMed 21941091 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2008 to primary completion in Jun 2008, 1 month.

Results were first posted in Sep 2017, 9 years 3 months after primary completion.

Of 19 phase 4 interventional studies under Herpes Zoster, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2008
First posted
May 20, 2008
StartActual
May 14, 2008
Primary completionActual
Jun 25, 2008
CompletionActual
Jun 25, 2008
Results first posted
Sep 26, 2017
Last update
Jun 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00681031
Responsible party
Sponsor
First posted
May 20, 2008
Start date
May 14, 2008
Primary completion
Jun 25, 2008
Completion
Jun 25, 2008
Results posted
Sep 26, 2017
Last update
Jun 29, 2021

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion